U.S. Life Sciences Stock News

Cable One (CABO) just posted fourth quarter FY 2025 revenue of US$363.7 million with a basic EPS loss of US$1.35, compared to a loss of US$18.71 on revenue of US$387.2 million in the prior year’s fourth quarter. Over the past six reported quarters, revenue has ranged between US$363.7 million and US$393.6 million, while basic EPS has swung from a profit of US$15.33 to a loss of US$77.70. This is prompting investors to focus closely on how these shifts are feeding through to underlying margins...

TTEC Holdings (TTEC) closed out FY 2025 with fourth quarter revenue of US$570 million and a basic EPS loss of US$3.55, alongside a net loss of US$172 million, setting a challenging tone around profitability. Over the last six reported quarters, revenue has moved in a tight band between US$513 million and US$570 million, while quarterly EPS has swung from a small profit of US$0.03 in early 2025 to losses. On a trailing twelve month view, EPS sits at a loss of US$3.99 on revenue of about US$2.1...

If you are wondering whether Paycom Software's current share price lines up with its underlying worth, this breakdown will help you size up what you are really paying for. The stock last closed at US$125.83, with returns of 9.7% over 7 days but declines of 9.9% over 30 days, 17.4% year to date and 42.3% over 1 year, which may have changed how investors view both its potential and its risks. Recent coverage has focused on Paycom's position in the payroll and HR software space, including...

Organon (OGN) is back on investors radar after releasing detailed sub analysis data from its Phase 3 ADORING trials, which showed that VTAMA cream improved sleep outcomes in children with atopic dermatitis and their families. See our latest analysis for Organon. Despite the encouraging VTAMA data, Organon’s recent share price performance has been weak, with a 30 day share price return of negative 18.0% and a 1 year total shareholder return decline of 50.6%, suggesting sentiment remains...

CoreWeave (CRWV) FY 2025 results: rapid top line expansion alongside ongoing losses CoreWeave (CRWV) has just posted its FY 2025 numbers, with fourth quarter revenue of US$1.6b and a basic EPS loss of US$0.83, alongside trailing twelve month revenue of US$5.1b and a loss of US$2.68 per share. Over the past six reported quarters, the company has seen revenue move from US$583.9m in Q3 2024 to US$1.6b in Q4 2025. Quarterly basic EPS has ranged from a loss of US$1.82 in Q3 2024 to a loss of...

Alliant Energy (LNT) is back in focus after multiple research firms updated their views following the company’s fourth quarter and full year 2025 earnings, its reaffirmed 2026 guidance, and progress on large customer projects. See our latest analysis for Alliant Energy. The recent earnings release and reaffirmed 2026 guidance appear to have supported a stronger tone in the stock, with a 9.2% 1 month share price return and a 10.3% year to date share price return sitting alongside a 15.7% 1...

International Paper has already decided to permanently close its Georgetown, South Carolina container plant by year-end 2026, after earlier shutting its local pulp and paper mill and selling its global cellulose fibers business, while also facing higher natural-gas costs from recent winter storms. At the same time, the company is preparing to split into two independent regional businesses, North America and EMEA, shifting away from global packaging deals toward a leaner, region-focused...

Personalis (PSNL) just posted its FY 2025 figures with Q4 revenue of about US$17.3 million and a basic EPS loss of roughly US$0.26, alongside a trailing twelve month EPS loss of about US$0.91 on revenue of roughly US$69.6 million. Over recent quarters, the company has seen quarterly revenue move between about US$14.5 million and US$20.6 million, while quarterly basic EPS losses have ranged from roughly US$0.18 to US$0.26. This keeps the focus squarely on when scale can start to ease those...

Biogen is advancing its Alzheimer’s treatment pipeline, with mid year clinical results for its BIIB080 drug candidate expected in the coming months. The company is also progressing other neurology programs, including felzartamab and the early Alzheimer’s therapy Leqembi. Investors are watching these developments closely as the outcomes could influence sentiment on NasdaqGS:BIIB. Biogen, trading on NasdaqGS:BIIB, last closed at $191.8. The stock is up 9.7% over the past 30 days, 7.9% year to...

Via Transportation (VIA) FY 2025 earnings recap Via Transportation (VIA) just closed out FY 2025 with Q4 revenue of US$118.9 million and a basic EPS loss of US$0.28, while trailing twelve month revenue reached US$434.3 million against a full year EPS loss of US$1.21. The company has seen quarterly revenue move from US$83.3 million in Q3 2024 to US$118.9 million in Q4 2025, as basic EPS ranged between a loss of US$1.70 and US$0.28 over the same stretch, and over the last year management...

Puma Biotechnology (PBYI) closed FY 2025 with Q4 revenue of US$75.5 million and basic EPS of US$0.27, alongside net income of US$13.4 million. Its trailing 12 month revenue came in at US$228.4 million with basic EPS of US$0.62 and net income of US$31.1 million. Over recent periods, the company has seen quarterly revenue range from US$46.0 million to US$80.5 million and basic EPS move between US$0.06 and US$0.98. This gives investors a clear view of how earnings scale with top line...

Emergent BioSolutions (EBS) has just wrapped up FY 2025 with Q4 revenue of US$148.7 million and basic EPS of a US$1.04 loss, capping a year in which quarterly revenue ranged from US$140.9 million to US$231.1 million and EPS swung between a profit of US$1.25 and a loss of US$0.22. Over the trailing 12 months to Q4 2025, the company recorded total revenue of US$742.9 million and basic EPS of US$0.98. This leaves investors to weigh improving headline profitability alongside still uneven...

Recent analyst commentary on V.F (VFC) has focused on weakness at the Vans brand, with J.P. Morgan issuing a downgrade that questions how quickly the company can reach its stated operating margin goals. See our latest analysis for V.F. The latest analyst downgrade comes after a mixed year for investors, with a 10.97% 90 day share price return and a 6.94% year to date share price return, in contrast with a 20.33% 1 year total shareholder return decline. This suggests that recent momentum has...

PRA Group (PRAA) closed out FY 2025 with Q4 revenue of US$333.4 million and basic EPS of US$1.46, while the trailing 12 month picture shows total revenue of about US$1.2 billion and a basic EPS loss of US$7.79. The company has seen quarterly revenue move from US$293.2 million in Q4 2024 to US$333.4 million in Q4 2025, with basic EPS shifting from US$0.47 to US$1.46 over the same period, alongside a wider loss on a trailing 12 month basis of US$305.1 million. Margins look compressed on the...

If you are wondering whether Southwest Gas Holdings at around US$88 per share offers good value today, you are not alone; many investors are trying to work out what a fair price looks like. The stock has returned 0.7% over the last week, 7.6% over the past month, 10.0% year to date, 21.3% over one year, 62.5% over three years and 51.5% over five years, which naturally raises questions about how its current price lines up with its fundamentals. Recent news flow around regulated utilities, gas...

United Natural Foods (NYSE:UNFI) hosted its 2026 Spring and Summer Selling Show, bringing together thousands of retailers and suppliers. The company unveiled nearly 50 new private label products across categories at the event. Key themes included healthier food offerings, private brand development, and growing interest in gut health. For you as an investor, this matters because UNFI sits at the center of the natural, specialty, and conventional grocery supply chain, connecting brands with...

FTI Consulting (FCN) has wrapped up FY 2025 with fourth quarter revenue of US$990.7 million and basic EPS of US$1.80, closing out a year where trailing twelve month revenue reached about US$3.8 billion and EPS came in at US$8.33. The company has seen revenue move from US$894.9 million in Q4 2024 to US$990.7 million in Q4 2025, while quarterly EPS shifted from US$1.41 to US$1.80. This may set the stage for investors to focus on how its 7.1% net margin and forecast earnings growth shape the...

If you are wondering whether F.N.B at around US$16.99 is still offering value, you are not alone. This article is built to help you make sense of where the stock stands on price versus fundamentals. The share price has seen mixed moves recently, with a 7 day return of 7.3% decline, a 30 day return of 1.4% decline, but a 1 year return of 18.1% and a 5 year return of 60.0%, which can change how investors think about both potential growth and risk. Recent coverage of regional banks and funding...

Howmet Aerospace (NYSE:HWM) announced a plan to acquire Consolidated Aerospace Manufacturing (CAM). The company intends to fund the deal using proceeds from a mix of newly announced and completed debt offerings. The transaction is expected to influence Howmet's operations, market positioning, and capital structure once finalized. Howmet Aerospace, a key supplier of engineered components for aerospace and industrial markets, is moving to expand its footprint with the CAM acquisition. For you...

Recently, D.R. Horton reiterated its full-year 2026 guidance but faced pressure as cautious housing-demand signals weighed on homebuilder sentiment. Analysts have turned more pessimistic on the company ahead of its April 21, 2026 earnings release, reflecting growing concern over sector headwinds. Next, we’ll examine how weakening housing-demand signals and more cautious analyst views may influence D.R. Horton’s existing investment narrative. The best AI stocks today may lie beyond giants...

Sprout Social (SPT) closed out FY 2025 with Q4 revenue of US$120.9 million and a basic EPS loss of US$0.18, while trailing twelve month figures show revenue of US$457.5 million and a basic EPS loss of US$0.73. Over recent quarters the company has seen revenue move from US$102.6 million in Q3 2024 to US$120.9 million in Q4 2025, with quarterly basic EPS losses ranging between US$0.16 and US$0.30, which keeps the focus firmly on how quickly the business can narrow those losses and improve...

Kymera Therapeutics (KYMR) closed FY 2025 with Q4 revenue of US$2.9 million and a basic EPS loss of US$0.97, while full year trailing twelve month figures showed revenue of US$39.2 million and a basic EPS loss of US$3.69. The company reported a decline in quarterly revenue from US$22.1 million in Q1 2025 to US$2.9 million in Q4, while basic EPS losses ranged between US$0.82 and US$0.97 across the year. This has set up a results season in which investors are weighing growth potential against...

Somnigroup International (SGI) came under pressure after its fourth quarter results and a new dividend declaration, as revenue missed analyst expectations even though sales and earnings for the period were higher than a year earlier. See our latest analysis for Somnigroup International. The fourth quarter earnings and dividend announcement came after a period where the share price has cooled slightly, with a 1-day share price return showing a 1.76% decline and a 90-day share price return...

Xylem (NYSE:XYL) has authorized a new share repurchase program of up to $1.5b. The program allows the company to buy back shares opportunistically over time. The announcement comes with Xylem shares recently trading around $129.56. Xylem, trading on the NYSE under the ticker XYL, is moving ahead with a sizeable $1.5b buyback plan at a share price of about $129.56. Over the past 3 years, the stock has returned 29.3%, and 37.1% over 5 years, which gives context for how management is choosing...